- Conditions
- Still´s Disease
- Interventions
- MAS825
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio • Portland, Oregon • Salt Lake City, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset
- Interventions
- anakinra, Placebo
- Biological · Drug
- Lead sponsor
- Swedish Orphan Biovitrum
- Industry
- Eligibility
- Not listed
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Beverly Hills, California • San Diego, California + 29 more
- Conditions
- Adult Onset Still's Disease
- Interventions
- Camoteskimab (CERC-007, AVTX-007, AEVI-007)
- Drug
- Lead sponsor
- Apollo Therapeutics Ltd
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • Ann Arbor, Michigan
- Conditions
- Still's Disease, Adult-Onset, Systemic Inflammation, Arthritis, Autoinflammatory Syndrome
- Interventions
- Not listed
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 1 Day to 100 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2050
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Inflammation, Familial Mediterranean Fever, Still's Disease, Adult-Onset
- Interventions
- IL-1 Trap
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
- Interventions
- Not listed
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Macrophage Activation Syndrome, Still's Disease, Adult-Onset, Stills Disease, Juvenile-Onset
- Interventions
- Chart review
- Other
- Lead sponsor
- Swedish Orphan Biovitrum
- Industry
- Eligibility
- 6 Months to 80 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Atlanta, Georgia • Cincinnati, Ohio + 1 more
- Conditions
- Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Arthritis, Juvenile, Adult Onset Still Disease
- Interventions
- Emapalumab
- Drug
- Lead sponsor
- Swedish Orphan Biovitrum
- Industry
- Eligibility
- 0 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio